102 related articles for article (PubMed ID: 38123304)
1. SKI-349, a Sphingosine Kinases 1/2 Inhibitor, Suppresses Cell Viability, Invasion, and AKT/mTOR Signaling Pathway, and Shows Synergistic Cytotoxic Effects with Sorafenib in Hepatocellular Carcinoma.
Chen L; Wang L; Han Z; Qin P; Niu G; Du J
Tohoku J Exp Med; 2024 Mar; 262(3):173-180. PubMed ID: 38123304
[TBL] [Abstract][Full Text] [Related]
2. Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma.
Hu Y; Luo Z; Cai S; Xie Q; Zheng S
Scand J Gastroenterol; 2024 Jun; 59(6):730-736. PubMed ID: 38426342
[TBL] [Abstract][Full Text] [Related]
3. CARMIL1 regulates liver cancer cell proliferation by activating the ERK/mTOR pathway through the TRIM27/p53 axis.
Ge Y; Xiao B; Zhao R; Li B; Yang S; He KF; Gu HJ; Zuo S
Int Immunopharmacol; 2024 Jun; 134():112139. PubMed ID: 38739978
[TBL] [Abstract][Full Text] [Related]
4. Ezetimibe Induces Paraptosis through Niemann-Pick C1-like 1 Inhibition of Mammalian-Target-of-Rapamycin Signaling in Hepatocellular Carcinoma Cells.
Yin Y; Wu C; Zhou Y; Zhang M; Mai S; Chen M; Wang HY
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38275586
[TBL] [Abstract][Full Text] [Related]
5. WEE Family Kinase Inhibitors Combined with Sorafenib Can Selectively Inhibit HCC Cell Proliferation.
Chen A; Yin K; Liu Y; Hu L; Cui Q; Wan X; Yang W
Curr Cancer Drug Targets; 2024 Jun; ():. PubMed ID: 38860904
[TBL] [Abstract][Full Text] [Related]
6. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
Lu M; Fei Z; Zhang G
Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
[TBL] [Abstract][Full Text] [Related]
7. Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/Stat3, ERK/MAPK, PI3K/Akt/mTOR signaling pathways.
Üremiş MM; Üremiş N; Türköz Y
Steroids; 2023 Oct; 198():109261. PubMed ID: 37355001
[TBL] [Abstract][Full Text] [Related]
8. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
[TBL] [Abstract][Full Text] [Related]
9. The sphingosine kinase inhibitor SKI-V suppresses cervical cancer cell growth.
Zhang Y; Cheng L; Shi X; Song Y; Chen XY; Chen MB; Yao J; Zhang ZQ; Cai S
Int J Biol Sci; 2022; 18(7):2994-3005. PubMed ID: 35541904
[TBL] [Abstract][Full Text] [Related]
10. FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma.
Tan XP; Xiong BH; Zhang YX; Wang SL; Zuo Q; Li J
Eur J Pharmacol; 2022 Sep; 931():175186. PubMed ID: 35977595
[TBL] [Abstract][Full Text] [Related]
11. BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway.
Li A; Zhang R; Zhang Y; Liu X; Wang R; Liu J; Liu X; Xie Y; Cao W; Xu R; Ma Y; Cai W; Wu B; Cai S; Tang X
Am J Transl Res; 2019; 11(9):5573-5585. PubMed ID: 31632530
[TBL] [Abstract][Full Text] [Related]
12. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
13. C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells.
Jiang S; Wang Q; Feng M; Li J; Guan Z; An D; Dong M; Peng Y; Kuerban K; Ye L
Appl Microbiol Biotechnol; 2017 Feb; 101(4):1535-1546. PubMed ID: 27807662
[TBL] [Abstract][Full Text] [Related]
14. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways.
Rosenberg L; Yoon CH; Sharma G; Bertagnolli MM; Cho NL
Carcinogenesis; 2018 May; 39(5):681-688. PubMed ID: 29538717
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib Treatment and Modulation of the Sphingolipid Pathway Affect Proliferation and Viability of Hepatocellular Carcinoma In Vitro.
Jakobi K; Beyer S; Koch A; Thomas D; Schwalm S; Zeuzem S; Pfeilschifter J; Grammatikos G
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244391
[TBL] [Abstract][Full Text] [Related]
17. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
[TBL] [Abstract][Full Text] [Related]
18. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
Dai N; Ye R; He Q; Guo P; Chen H; Zhang Q
Oncol Rep; 2018 Dec; 40(6):3235-3248. PubMed ID: 30272354
[TBL] [Abstract][Full Text] [Related]
19. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
[TBL] [Abstract][Full Text] [Related]
20. The anti-osteosarcoma cell activity by the sphingosine kinase 1 inhibitor SKI-V.
Sun X; Shan HJ; Yin G; Zhang XY; Huang YM; Li HJ
Cell Death Discov; 2022 Feb; 8(1):48. PubMed ID: 35115496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
